GLENMARK:NSE:NSE-Glenmark Pharmaceuticals Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1338.15

Change

0.00 (0.00)%

Market Cap

USD 347.26B

Volume

1.45M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-06 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

-0.80 (-0.04%)

USD 4,554.89B
DIVISLAB:NSE Divi's Laboratories Limited

-4.75 (-0.09%)

USD 1,441.57B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+81.40 (+2.40%)

USD 1,154.88B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-102.40 (-1.52%)

USD 1,121.95B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-11.70 (-1.09%)

USD 1,071.49B
MANKIND:NSE Mankind Pharma Ltd

+73.85 (+2.91%)

USD 1,033.59B
LUPIN:NSE Lupin Limited

+14.65 (+0.67%)

USD 998.11B
AUROPHARMA:NSE Aurobindo Pharma Limited

+7.45 (+0.51%)

USD 851.48B
ALKEM:NSE Alkem Laboratories Limited

+34.85 (+0.57%)

USD 740.60B
AJANTPHARM:NSE Ajanta Pharma Limited

-26.20 (-0.78%)

USD 418.19B

ETFs Containing GLENMARK:NSE

SCIF 0.00 % 0.83 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 56.39% 92% A 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.39% 92% A 85% B
Trailing 12 Months  
Capital Gain 94.15% 82% B 76% C+
Dividend Return 0.36% 33% F 25% F
Total Return 94.51% 82% B 76% C+
Trailing 5 Years  
Capital Gain 206.53% 55% F 52% F
Dividend Return 2.75% 27% F 25% F
Total Return 209.28% 55% F 52% F
Average Annual (5 Year Horizon)  
Capital Gain 36.51% 58% F 52% F
Dividend Return 37.09% 59% D- 53% F
Total Return 0.58% 60% D- 48% F
Risk Return Profile  
Volatility (Standard Deviation) 50.85% 46% F 49% F
Risk Adjusted Return 72.94% 71% C- 59% D-
Market Capitalization 347.26B 89% A- 88% B+

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector